Advertisement

Topics

BioTime Inc. Company Profile

18:47 EDT 22nd March 2019 | BioPortfolio

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime’s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime’s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime’s lead cell delivery clinical program is Renevia®, an investigational medical device being developed as an alternative for whole adipose tissue transfer procedures. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, AgeX Therapeutics, Inc.


News Articles [47 Associated News Articles listed on BioPortfolio]

BioTime Acquires Two Clinical─Stage Cell Therapy Product Candidates Addressing Significant Unmet Needs in Spinal Cord Injury and Immuno─Oncology

BioTime, Inc, and Asterias Biotherapeutics, Inc, announced that they have entered into a definitive merger agreement whereby BioTime will acquire all of the remaining outstanding common stock of Aster...

BioTime, Orbit Biomedical team up in dry-AMD

In an exclusive twelve-month deal, BioTime Inc. and start-up Orbit Biomedical Ltd. are collaborating on the delivery of BioTime’s dry age-related macular degeneration candidate using Orbit’s techn...

Asterias Biotherapeutics to merge with BioTime

US-based biotechnology firms BioTime and Asterias Biotherapeutics have entered into a definitive merger agreement to form an integrated company focussed...Read More... The post Asterias Biotherapeutic...

BioTime spins out its early-stage technology into new company

BioTime Inc (NYSEAMERICAN:BTX) CEO Brian Culley sat down with Proactive Investors at the 11th Annual LD Micro Main Event in Los Angeles.  BioTime specializes in regenerative medicine and util...

BioTime signs merger deal with Asterias Biotherapeutics

The merger of BioTime and Asterias Biotherapeutics will enable to create a major cell therapy company. As per terms of the deal, Asterias stockholders will secure 0.71 common The post BioTime signs m...

BioTime schließt Verkauf von AgeX-Anteilen an Juvenescence in Höhe von 43,2 Millionen USD ab

Erlös stellt BioTime ausreichend Kapital für die Finanzierung wichtiger Meilensteine aktueller Programme zur Verfügung, einschließlich Schlüsseldaten und Entscheidungen zu Renevia und OpRegen Bio...

Asterias and BioTime reverse merge to focus on cancer, neuro cell therapies

BioTime Inc. is re-acquiring an ownership stake in former subsidiary Asterias Biotherapeutics Inc., resulting in a merged cell therapy company in which Asterias will be the surviving entity and hold 1...

BioTime to Present at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer o...

Drugs and Medications [0 Results]

None

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

An industry update: the latest developments in therapeutic delivery covering September 2018.

The present industry update covers the period 1-30 September 2018, with information sourced from company press releases, regulatory and patent agencies as well as scientific literature. Various techno...

Clinical Trials [0 Results]

None

Companies [9 Associated Companies listed on BioPortfolio]

BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell techn...

BioTime Inc.

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime’s p...

BioTime, Inc. and Abcodia Ltd.

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell ...

BioTime, Inc. 

BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical ...

BioTime Incorporated

BioTime, Inc. (OTCBB: BTIM), based in Emeryville, California, is engaged in the research and development of aqueous-based synthetic solutions that may be used as plasma expanders, organ preservation s...

More Information about "BioTime Inc." on BioPortfolio

We have published hundreds of BioTime Inc. news stories on BioPortfolio along with dozens of BioTime Inc. Clinical Trials and PubMed Articles about BioTime Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioTime Inc. Companies in our database. You can also find out about relevant BioTime Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...


Corporate Database Quicklinks



Searches Linking to this Company Record